Lisata Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 10, 2025, reports the results of the 2025 Annual Meeting of Stockholders for Lisata Therapeutics, Inc. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol LSTA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders approved five proposals at the Annual Meeting:
- Proposal 1 (Director Election): Re-elected Mohammad Azab, M.D., M.B.A. and Steven Klosk as Class III directors.
- Mohammad Azab: 3,809,977 For; 248,301 Against; 137,562 Abstaining.
- Steven Klosk: 3,788,000 For; 271,233 Against; 136,607 Abstaining.
- Proposal 2 (ESPP Amendment): Approved an increase in shares available under the 2017 Employee Stock Purchase Plan from 113,333 to 158,333.
- Results: 3,523,229 For; 294,116 Against; 378,495 Abstaining.
- Proposal 3 (Auditor Ratification): Ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Results: 6,226,674 For; 64,171 Against; 136,348 Abstaining.
- Proposal 4 (Say-on-Pay): Approved, on a non-binding advisory basis, the executive compensation of named executive officers.
- Results: 3,496,571 For; 551,109 Against; 148,160 Abstaining.
- Proposal 5 (Say-on-Pay Frequency): Approved a one-year frequency for future advisory votes on executive compensation.
- Results: 3,967,202 For (1 year); 7,923 For (2 years); 81,914 For (3 years); 138,801 Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves solely to disclose the voting results of the Annual Meeting.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on April 25, 2025, for detailed descriptions of the proposals and executive compensation details.
- Confirm the impact of the increased share pool (158,333 shares) on future dilution under the Employee Stock Purchase Plan.
- Review the company's upcoming financial reports for the fiscal year ending December 31, 2025, as this 8-K contains no financial data.